6 citations
,
June 2021 in “EClinicalMedicine” In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.
3 citations
,
September 2021 in “EClinicalMedicine” In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.
1 citations
,
August 2022 in “Frontiers in Medicine” This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.
In a randomized, double-blinded, placebo-controlled clinical trial, this study found that the botanical-based compound ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.
January 2022 in “Clinical Cases in Dermatology” This review discusses the causes, diagnosis, and treatment approaches for telogen effluvium but presents no new clinical findings; novel treatments like ALRV5XR are highlighted as promising.